糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Glycated Hemoglobin A1c (HbA1c) ,etc. by FLIA (Flow Luminescence Immunoassay)
Glycosylated Hemoglobin; Hemoglobin A1c; Hb1c; HbAIc; HbAIc
（注：?jiǎn)未位鞙y(cè)多因子不超過8個(gè)指標(biāo) ）
- 編號(hào)LMA190Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)1.5h
- 檢測(cè)范圍0.98-1000pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.327 pg/mL.
- 樣本類型Serum, plasma and erythrocyte lysates
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2359 ¥ 2449 ¥ 2586 ¥ 2767 ¥ 2948 ¥ 3221 ¥ 3629 ¥ 4536 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 94-102 | 98 |
| EDTA plasma(n=5) | 79-98 | 85 |
| heparin plasma(n=5) | 96-103 | 99 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 78-89% | 96-103% | 88-96% | 79-91% |
| EDTA plasma(n=5) | 80-95% | 80-101% | 88-102% | 87-98% |
| heparin plasma(n=5) | 88-95% | 93-101% | 79-94% | 90-101% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠、檢測(cè)溶液A）標(biāo)準(zhǔn)品或樣本50μL及磁珠10μL，加檢測(cè)溶液A50μL，
37°C酶標(biāo)板振蕩器孵育60分鐘；
3. 磁吸洗板3次；
4. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
5. 磁吸洗板3次；
6. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠、標(biāo)記VEGFA，標(biāo)記的糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)和未標(biāo)記的糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體競(jìng)爭(zhēng)結(jié)合，然后將未結(jié)合物洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈負(fù)相關(guān)。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| NPA190Hu01 | 糖化血紅蛋白A1c(HbA1c)天然蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA190Hu01 | 糖化血紅蛋白A1c(HbA1c)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA190Hu71 | 糖化血紅蛋白A1c(HbA1c)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAA190Hu21 | 糖化血紅蛋白A1c(HbA1c)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA190Hu22 | 糖化血紅蛋白A1c(HbA1c)單克隆抗體 | WB; IHC; ICC; IP. |
| CEA190Hu | 糖化血紅蛋白A1c(HbA1c)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CCA190Hu | 糖化血紅蛋白A1c(HbA1c)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA190Hu | 糖化血紅蛋白A1c(HbA1c)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA190Hu01 | 糖化血紅蛋白A1c(HbA1c)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
| KSA190Hu11 | 糖化血紅蛋白A1c(HbA1c)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| J Am Coll Nutr | The Effect of Vitamin D Supplementation on Glycemic Control and Lipid Profile in Patients with Type 2 Diabetes Mellitus [PubMed: 26391639] |
| Journal of the American College of Nutrition | The Effect of Vitamin D Supplementation on Glycemic Control and Lipid Profile in Patients with Type 2 Diabetes Mellitus. [pubmed:26391639] |
| Journal of Endocrinology and Metabolism | Circulating Betatrophin and Hepatocyte Growth Factor in Type 2 Diabetic Patients: Their Relationship With Disease Prognosis [405] |
| Molecular nutrition & food research | Chicory inulin ameliorates type 2 diabetes mellitus and suppresses JNK and MAPK pathways in vivo and in vitro [pubmed:28105758] |
| 33 | d-Ribose as a Contributor to Glycated Haemoglobin [pubmed:29033370] |
| Journal of Functional Foods | Hypoglycemic effect of Hypericum attenuatum Choisy extracts on type 2 diabetes by regulating glucolipid metabolism and modulating gut microbiota [] |
| West Indian Medical Journal | Plasma Cellular Hypoxia, Mitochondrial Dysfunction, Disease Risk and Prognostic Factors in Type 2 Diabetic Patients in Saudi Arabia. [] |
| Journal of Occupational and Environmental?Hygiene | Stressors, allostatic load, and health outcomes among women hotel housekeepers: A pilot study [Pubmed: 30615593] |
| Cell?Reports | Parabacteroides distasonis Alleviates Obesity and Metabolic Dysfunctions via Production of Succinate and Secondary Bile Acids [Pubmed: 30605678] |
| Journal of Agricultural and Food Chemistry | Gymnemic acid alleviates type 2 diabetes mellitus and suppresses endoplasmic reticulum stress in vivo and in vitro [] |
| Journal of Clinical Medicine | 1H Nuclear Magnetic Resonance (NMR)-Based Cerebrospinal Fluid and Plasma Metabolomic Analysis in Type 2 Diabetic Patients and Risk Prediction for Diabetic?… [Pubmed: 31248127] |
| Food & Function | Gymnemic Acid Alleviates Inflammation and Insulin Resistance via PPARδ-and NFκB-mediated pathways in db/db mice. [] |
| Obesity Surgery | Duodenal-Jejunal Bypass Ameliorates Type 2 Diabetes Mellitus by Activating Insulin Signaling and Improving Glucose Utilization in the Brain [Pubmed: 31605365] |
| Acta Diabetologica | Modulation of gut microbiota contributes to effects of intensive insulin therapy on intestinal morphological alteration in high-fat-diet-treated mice [Pubmed: 31749050] |
| Open Access Macedonian Journal of Medical Sciences | Inhibition of Receptor for Advanced Glycation End Products as New Promising Strategy Treatment in Diabetic Retinopathy [Pubmed: 32165929] |
| Cell Reports | Activation of a Specific Gut Bacteroides-Folate-Liver Axis Benefits for the Alleviation of Nonalcoholic Hepatic Steatosis [Pubmed: 32783933] |
| The effects of different intensity endurance and resistance exercise on diabetic-related blood profiles in impaired glucose tolerance mice [] | |
| Revista Internacional de Andrologia | Relation of pharmacopenile duplex ultrasonography parameters and glycated hemoglobin (HbA1c) in diabetic patients with erectile dysfunction [33334711] |
| Advanced Theory and Simulations? | Identification of Key Contributive Compounds in a Herbal Medicine: A Novel Mathematic?aBiological Evaluation Approach [] |
| Dis Markers | The Roles of Liver Inflammation and the Insulin Signaling Pathway in PM2. 5 Instillation-Induced Insulin Resistance in Wistar Rats [34745386] |
| Antioxidants | Antioxidant Effect of Tyr-Ala Extracted from Zein on INS-1 Cells and Type 2 Diabetes High-Fat-Diet-Induced Mice [Pubmed:35740008] |
| P001–Inv. Clínica [] |
